RATIO-FLUTICASONE 50 MCG
FLUTICASONE PROPIONATE : 50 MCG · DIN 02296071 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is RATIO-FLUTICASONE?
RATIO-FLUTICASONE 50 MCG contains FLUTICASONE PROPIONATE : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02296071, held by TEVA CANADA LIMITED, supplied as METERED-DOSE PUMP for NASAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Jul-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02296071 |
|---|---|
| Brand name | RATIO-FLUTICASONE |
| Generic / active ingredient | FLUTICASONE PROPIONATE : 50 MCG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 50 MCG |
| Dosage form | METERED-DOSE PUMP |
| Route of administration | NASAL |
| Schedule | Prescription |
| ATC code | R01AD08 FLUTICASONE |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Jul-2021 |
| Original market date | 2007-06-07 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code R01AD08 FLUTICASONE. 4 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 24HR NASAL ALLERGY RELIEF | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | MARKETED | DIN 02460513 |
| APO-FLUTICASONE | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | MARKETED | DIN 02294745 |
| FLONASE ALLERGY RELIEF | 50 MCG | SPRAY, METERED DOSE | HALEON CANADA ULC | MARKETED | DIN 02248307 |
| TEVA-FLUTICASONE | 50 MCG | METERED-DOSE PUMP | TEVA CANADA LIMITED | MARKETED | DIN 02453738 |
| ALLERGY RELIEF NASAL SPRAY | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | APPROVED | DIN 02460475 |
| FLONASE - AEM-SUS NAS 50MCG/MD | 50 MCG | METERED-DOSE PUMP | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02213672 |
| FLONASE AEM-SUS 50MCG/AEM | 50 MCG | SUSPENSION ; METERED-DOSE AEROSOL | GLAXO CANADA INC | CANCELLED POST MARKET | DIN 02048043 |
| NU-FLUTICASONE | 50 MCG | SPRAY, METERED DOSE | NU-PHARM INC | CANCELLED (UNRETURNED ANNUAL) | DIN 02336405 |
Who else supplies FLUTICASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FLUTICASONE appears in 9252 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.